Clinical Trial Update: A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C [Phase 2]

View source ↗

Summary

The document notes the completion of a Phase II dose-escalation study of PEG-IFN-SA with ribavirin in interferon-naive patients with chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG-IFN-SA (pegylated interferon-alpha)
• Ribavirin (ribavirin)

Snippet

Sponsor: Beijing Kawin Technology Share-Holding Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED